[Double-blind study on therapy with new drugs in stomach and duodenal ulcers].
Patients with ulcers of the stomach and the duodenum were treated with Pirenzepin and the new H2-inhibitor Renitidin. The effects were evaluated on the basis of a double blind trial. After the endoscopic diagnosis repeated examinations were practiced until three weeks after the beginning of the treatment. The best results were found in duodenal ulcers after treatment with Renitidin. 86,6% of the ulcers were healed after 3 weeks of treatment. This results was statistically significant compared with a group of patients treated with a placebo. With gastrozepin 77,2% of patients were successfully treated. In ulcers of the stomach the results were not so good and statistically insignificant. Side effects were not found. Until now it is not possible to decide which substance guarantees better results.
D000328:Adult; D000897:Anti-Ulcer Agents / Q000627:therapeutic use*; D001570:Benzodiazepinones / Q000627:therapeutic use*; D004311:Double-Blind Method; D004381:Duodenal Ulcer / Q000188:drug therapy*; D004384:Duodenoscopy; D005260:Female; D005663:Furans / Q000627:therapeutic use*; D005744:Gastric Acid / Q000378:metabolism; D005773:Gastroscopy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010890:Pirenzepine; D011899:Ranitidine; D013276:Stomach Ulcer / Q000188:drug therapy*; D014945:Wound Healing / Q000187:drug effects
D000897:Anti-Ulcer Agents; D001570:Benzodiazepinones; D005663:Furans; D010890:Pirenzepine; D011899:Ranitidine
Doppelblindstudie zur Therapie mit neuen Pharmaka bei Magen- und Zwölffingerdarmgeschwüren.